Protective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery

Launched by NANJING MEDICAL UNIVERSITY · Dec 4, 2024

Keywords

ClinConnect Summary

The PANDA X trial is a study looking at a traditional Chinese medicine called Angong Niuhuang Pills (ANP) to see if it can help patients who experience brain problems after heart surgery. Neurologic dysfunction, which means issues with brain function, can happen after surgeries that involve the heart and lungs. This trial will focus on patients who are 18 years or older and have recently undergone cardiovascular surgery, showing moderate to severe neurologic dysfunction. Specifically, they will be looking for patients who have a certain level of brain impairment, measured by a scoring system, and who experienced symptoms within the last day and a half.

If eligible, participants will be given the chance to receive ANP, which has shown some promise in earlier studies for protecting the brain and reducing swelling. The trial is still in the planning stages and has not started recruiting participants yet. It's important to note that certain health conditions, like liver failure or recent use of ANP, might prevent someone from joining the study. Overall, this trial aims to explore whether ANP can improve brain health after heart surgery and help patients recover better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) an age \> 18 years,
• • (2) underwent cardiovascular surgery,
• • (3) diagnosis of acute neurologic dysfunction, including but not limited acute cerebral infarction of the internal carotid artery system,
• • (4) a National Institutes of Health Stroke Scale (NIHSS) score ranging from 10 to 20,
• • (5) a time from symptom onset to randomization within 36 h,
• • (6) provision of informed consent.
• Exclusion Criteria:
• • (1) not suitable for taking ANP after the dialectical process by a traditional Chinese medical doctor,
• • (2) received ANP within 1 month before stroke onset,
• • (3) liver failure,
• • (4) declined to participate in this study.